Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Thursday, February 1, 2007

Kimball Genetics Inc has launched a warfarin sensitivity DNA test for research and investigational purposes. The test determines the presence of specific variations in the CYP2C9 and VKORC1 genes that confer sensitivity to warfarin. The DNA test identifies patients who are sensitive to warfarin and, therefore, require a lower dose to achieve their target levels and may be at increased risk for bleeding complications.

The FDA Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Sciences has recommended testing for genetic variations in patients requiring warfarin therapy. This recommendation is likely to be reflected on the drug's label soon. The company expects the DNA test to be available for routine clinical use sometime this year.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues